A Phase IIa Study to Investigate Safety, Pharmacokinetics, and Efficacy of Odiparcil in Patients 16 Years and Above With Mucopolysaccharidosis (MPS) Type VI

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 May 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Odiparcil (Primary)
Indications Mucopolysaccharidosis VI
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
Acronyms iMProveS
Sponsors Inventiva Pharma

03 Feb 2020 According to a Inventia media release, the study also met itssafety primary objective, confirming the good safety profile of odiparcil
03 Feb 2020 According to an Inventia media release, the company will present a poster based on this trial at the 16th Annual WORLD Symposium taking place from February 10 to 13, 2020 at the Hyatt Regency Orlando, Orlando, Florida
18 Dec 2019 According to an Inventiva Pharma media release, data will be presented during a dedicated conference call and webcast on Thursday, December 19, 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com